HEB - Hemispherx Biopharma, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.2201
+0.0189 (+9.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.2012
Open0.2156
Bid0.2000 x 100
Ask0.7000 x 800
Day's Range0.2065 - 0.2300
52 Week Range0.1500 - 0.6500
Volume651,973
Avg. Volume258,065
Market Cap10.509M
Beta (3Y Monthly)0.52
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?
    Simply Wall St.6 months ago

    How Has Hemispherx Biopharma Inc’s (NYSEMKT:HEB) Performed Against The Industry?

    After reading Hemispherx Biopharma Inc’s (AMEX:HEB) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...

  • Zacks Small Cap Research10 months ago

    HEB: Recent Advancements…What Do They Imply?

    With the stock up 50% over the past 3 months, we believe HEB (HEB) is starting to look like an attractive investment.  Since our prior report (November 14, 2017), Hemispherx has made some progress in their Ampligen product development cycle that could potentially prove positive for their stock. ➢ Hemispherx obtained ANMAT approval in Argentina, one of South America's largest markets, in August 2017.  Ampligen is available in Europe through an Early Access Program (EAP).  In the U.S., Ampligen has undergone two randomized, placebo-controlled pivotal trials.  The firm is currently focused on preparing an NDA and confirmatory trial for Ampligen.  Meanwhile, Ampligen is available for patients under a cost recovery program (compassionate care) – which means that Hemispherx cannot make a profit on Ampligen sales but can recover its costs.  Hemispherx received an approval from the FDA to increase the price of one vial from $75 to $200.

  • GuruFocus.com10 months ago

    Here's Why the 2 Latest Hemispherx BioPharma Announcements Are Important

    A look at the latest news from Hemispherx and what it means for the company

  • Capital Cube11 months ago

    ETFs with exposure to Hemispherx Biopharma, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Hemispherx Biopharma, Inc. Here are 5 ETFs with the largest exposure to HEB-US. Comparing the performance and risk of Hemispherx Biopharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017
    Capital Cubelast year

    Hemispherx Biopharma, Inc. :HEB-US: Earnings Analysis: Q3, 2017 By the Numbers : December 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Hemispherx Biopharma, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Hemispherx Biopharma, Inc. – Sarepta Therapeutics, Inc., Gilead Sciences, Inc., Pfizer Inc., Baxter International Inc., Merck & Co., Inc., Valeant Pharmaceuticals International Inc, GlaxoSmithKline plc Sponsored ADR and ... Read more (Read more...)